A 19.74 per cent increase in earnings in Q3 of this year has been reported by the Ibn Sina Pharmaceutical Industry Limited.
The company stated, via a filing with the Dhaka Stock Exchange on April 25, that its earnings per share (EPS) was Tk 2.79 for the Q3 (July-March) of FY2021, which was Tk 2.33 in the same time frame in FY2020.
Its EPS was Tk 10.92 for July 2020-March 2021 as against Tk 9.63 for the same period a year ago.
Meanwhile, net operating cash flow per share (NOCFPS) of the pharmaceutical company was Tk 14.17 for July 2020-March 2021 as against Tk 9.54 for the same period of the previous.
Its net asset value (NAV) per share was Tk 64.08 as of March 31, 2021, and Tk 56.88 as of June 30, 2020.